Skip to main content

JHOP - March 2024 Vol 14 Special Feature

DOWNLOAD EDITORIAL PDF

Download Hopa Abstracts PDF

New Year, New HOP(A): Return of the Annual Conference Research Abstracts

Sara S. Kim, BS, PharmD, BCOP; Adam J. DiPippo, PharmD, BCOP

Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists

Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course

Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas

Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy

Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence

Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study

Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update

First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update

Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service

Incidence and Outcomes of Pneumonitis/Interstitial Lung Disease in Patients Receiving Trastuzumab Deruxtecan

Number-Needed-to-Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Pharmacist-Led Monitoring for Patients Initiating PARP Inhibitor Therapy

Patient Perspective: Logistics of Intravenous Iron Administration and Adherence to Therapy

Predictive Factors of Dose Reduction Among Patients Treated With Palbociclib for Advanced or Metastatic Breast Cancer in a Real-World Setting

Real-Life Study: Evaluation of the Safety of PARP Inhibitors in Ovarian Cancer at the Centre Hospitalier de l’Université de Montréal (CHUM)

Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After High-Dose Cytarabine Consolidation Chemotherapy (the REMEDY Trial)

Survey of PGY-2 Oncology Residency Program Directors to Assess Current Resources and Effects on Burnout

Taxane Titration: To Prime or Not to Prime?

Treatment and Outcomes Associated With Caplacizumab in the Management of Acquired Thrombotic Thrombocytopenic Purpura

Pharmacist Interventions Resulting From a Health System Specialty Pharmacy 14-Day Oncology Check-In Protocol

Comparison of the Efficacy of Generic Plerixafor Versus Mozobil as Adjunct Peripheral Blood Stem-Cell Mobilization Agents in Patients With Multiple Myeloma

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate vs Tacrolimus and Methotrexate as GVHD Prevention Following Allogeneic Stem Cell Transplant With Myeloablative Conditioning

Real-World Clinical Outcomes With Fostamatinib for the Treatment of Refractory Chronic Immune Thrombocytopenia

Unlocking Geographic Disparities in Lung Cancer Incidence Calls for Tailored Interventions and Pharmacist Partnerships